
Site burden is now measured through satisfaction surveys, in-the-moment check-ins, and adoption patterns, but each method catches a different moment, and the gaps between them decide whether teams can act before burden becomes risk.
SGS, a life sciences, pharmaceutical, clinical, and bioanalytical contract solutions provider, announced that it has successfully implemented advanced techniques for the collection and use of peripheral blood mononuclear cells for early phase clinical trials at its Clinical Pharmacology Unit in Antwerp, Belgium.
Read the full release






